Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Antisense Therapy Market Research Report Information By Application (Genetic Disease, Cancer, Infectious Disease, Neurodegenerative Disorders, Cardiometabolic & Renal Disorders, Ocular Disorders, Respiratory Disorders, Skin Disorders, Others), By Route of Administration (Intravenous Injections, Intrathecal Injections) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032


ID: MRFR/Pharma/19779-HCR | 128 Pages | Author: Rahul Gotadki| May 2024

 


Market Segmentation


Antisense Therapy Application Outlook (USD Billion, 2018-2032)




  • Genetic Disease




  • Cancer




  • Infectious Disease




  • Neurodegenerative Disorders




  • Cardiometabolic & Renal Disorders




  • Ocular Disorders




  • Respiratory Disorders




  • Skin Disorders






  • Others




Antisense Therapy Route of Administration Outlook (USD Billion, 2018-2032)




  • Intravenous Injections




  • Intrathecal Injections




Antisense Therapy Regional Outlook (USD Billion, 2018-2032)


 




  • North AmericaOutlook (USD Billion, 2018-2032)




    • North America Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • North America Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • USOutlook (USD Billion, 2018-2032)




    • US Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • US Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • CANADA Outlook (USD Billion, 2018-2032)




    • CANADA Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • CANADA Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections








  • Europe Outlook (USD Billion, 2018-2032)




    • Europe Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Europe Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • Germany Outlook (USD Billion, 2018-2032)




    • Germany Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Germany Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • France Outlook (USD Billion, 2018-2032)




    • France Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others s






    • France Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • UK Outlook (USD Billion, 2018-2032)




    • UK Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • UK Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • ITALY Outlook (USD Billion, 2018-2032)




    • ITALY Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • ITALY Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • SPAIN Outlook (USD Billion, 2018-2032)




    • Spain Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Spain Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • Rest Of Europe Outlook (USD Billion, 2018-2032)




    • Rest Of Europe Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • REST OF EUROPE Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections








  • Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Asia-Pacific Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Asia-Pacific Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • China Outlook (USD Billion, 2018-2032)




    • China Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • China Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • Japan Outlook (USD Billion, 2018-2032)




    • Japan Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Japan Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • India Outlook (USD Billion, 2018-2032)




    • India Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • India Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • Australia Outlook (USD Billion, 2018-2032)




    • Australia Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Australia Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Rest of Asia-Pacific Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Rest of Asia-Pacific Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections








  • Rest of the World Outlook (USD Billion, 2018-2032)




    • Rest of the World Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Rest of the World Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • Middle East Outlook (USD Billion, 2018-2032)




    • Middle East Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Middle East Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • Africa Outlook (USD Billion, 2018-2032)




    • Africa Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Africa Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections






    • Latin America Outlook (USD Billion, 2018-2032)




    • Latin America Antisense Therapy by Application




      • Genetic Disease




      • Cancer




      • Infectious Disease




      • Neurodegenerative Disorders




      • Cardiometabolic & Renal Disorders




      • Ocular Disorders




      • Respiratory Disorders




      • Skin Disorders




      • Others






    • Latin America Antisense Therapy by Route of Administration




      • Intravenous Injections




      • Intrathecal Injections







Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents

1. Executive summary

2. Market Introduction

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. Research Methodology

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. Market Dynamics

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. Market Factor Analysis

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL ANTISENSE THERAPY MARKET,BY Application

6.1. Overview

6.2. Genetic Disease

6.3. Cancer

6.4. Infectious Disease

6.5. Neurodegenerative Disorders

6.6. Cardiometabolic & Renal Disorders

6.7. Ocular Disorders

6.8. Respiratory Disorders

6.9. Skin Disorders

6.10. Others

7. GLOBAL ANTISENSE THERAPY MARKET,BY Route of Administration

7.1. Overview

7.2. Intravenous Injections

7.3. Intrathecal Injections

8. GLOBAL ANTISENSE THERAPY MARKET, by Region

8.1. Overview

8.1. North America

8.1.1. US

8.1.2. Canada

8.2. Europe

8.2.1. Germany

8.2.2. France

8.2.3. UK

8.2.4. Italy

8.2.5. Spain

8.2.6. Rest of Europe

8.3. Asia-Pacific

8.3.1. China

8.3.2. India

8.3.3. Japan

8.3.4. South Korea

8.3.5. Australia

8.3.6. Rest of Asia-Pacific

8.4. Rest of the World

8.4.1. Middle East

8.4.2. Africa

8.4.3. Latin America

9. Competitive Landscape

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Antisense Therapy Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Antisense Therapy Market,

9.7. Key developments and Growth Strategies

9.7.1. New ProductLaunch/Service Deployment

9.7.2. Merger &Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income,2022

9.8.2. Major Players R&D Expenditure.2022

10. Company ProfileS

10.1. GSK plc;

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Products Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Olix Pharmaceuticals, Inc;

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Products Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Sanofi;

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Products Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Alnylam Pharmaceuticals, Inc.;

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Products Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Arbutus Biopharma;

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Products Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Benitec Biopharma Inc.;

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Products Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Silence Therapeutics;

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Products Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Ionis Pharmaceuticals, Inc;

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Products Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Bio-Path Holdings Inc..;

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Products Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Antisense Therapeutics Limited;

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Products Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

11. Appendix

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 Global Antisense Therapy Market, Synopsis, 2018-2032

TABLE 2 Global Antisense Therapy Market, Estimates &Forecast, 2018-2032(USD BILLION)

TABLE 3 GLOBAL ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 4 GLOBAL ANTISENSE THERAPY MARKET,BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 5 North America: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 6 North America: ANTISENSE THERAPY MARKET,BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 7 US: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 8 US: ANTISENSE THERAPY MARKET,BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 9 Canada: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 10 Canada: ANTISENSE THERAPY MARKET,BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 1 Europe: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 2 Europe: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 3 germany: ANTISENSE THERAPY MARKET,BY Application,2018-2032 (USD BILLION)

TABLE 4 germany: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 5 FRANCE: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 6 FRANCE: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 7 italy: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 8 italy: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 9 spain: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 10 spain: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 11 UK: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 12 UK: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 13 rest of europe: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 14 rest of europe: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 15 Asia-Pacific: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 16 Asia-Pacific: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 17 japan: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 18 japan: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 19 china: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 20 china: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 21 india: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 22 india: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 23 australia: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 24 australia: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 25 south korea: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 26 south korea: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 27 rest of asia-pacific: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 28 rest of asia-pacific: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 29 rest of the world: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 30 rest of the world: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 31 Middle east: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 32 Middle east: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 33 Africa: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 34 Africa: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

TABLE 35 Latin america: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)

TABLE 36 Latin america: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 Research Process

FIGURE 2 Market Structure for the Global Antisense Therapy Market

FIGURE 3 Market Dynamics for the Global Antisense Therapy Market

FIGURE 4 Global Antisense Therapy Market, Share (%), BY Application, 2022

FIGURE 5 Global Antisense Therapy Market, Share (%), BY Route of Administration , 2022

FIGURE 6 Global Antisense Therapy Market, Share (%), by Region, 2022

FIGURE 7 north AMERICA: ANTISENSE THERAPY MARKET, SHARE (%), BY REGION, 2022

FIGURE 8 Europe: ANTISENSE THERAPY MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 Asia-Pacific: ANTISENSE THERAPY MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 Rest of the world: ANTISENSE THERAPY MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 Global Antisense Therapy Market: Company Share Analysis, 2022 (%)

FIGURE 12 GSK plc: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 GSK plc: SWOT ANALYSIS

FIGURE 14 Olix Pharmaceuticals, Inc.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 Olix Pharmaceuticals, Inc.:SWOT ANALYSIS

FIGURE 16 Sanofi:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 Sanofi:SWOT ANALYSIS

FIGURE 18 Alnylam Pharmaceuticals, Inc.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 Alnylam Pharmaceuticals, Inc.:SWOT ANALYSIS

FIGURE 20 Arbutus Biopharma.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 Arbutus Biopharma.:SWOT ANALYSIS

FIGURE 22 Benitec Biopharma Inc:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 Benitec Biopharma Inc:SWOT ANALYSIS

FIGURE 24 Silence Therapeutics: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 Silence Therapeutics: SWOT ANALYSIS

FIGURE 26 Ionis Pharmaceuticals, Inc.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 Ionis Pharmaceuticals, Inc.:SWOT ANALYSIS

FIGURE 28 Bio-Path Holdings Inc i:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 Bio-Path Holdings Inc:SWOT ANALYSIS

FIGURE 30 Antisense Therapeutics Limited..: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 Antisense Therapeutics Limited.:SWOT ANALYSIS

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.